"Winning the Start-up Pitch Presentation at BIOSPAIN among 43 high-level presentations was a turning point for us"

Innovation requires more than ideas: it needs spaces where projects can gain visibility, attract strategic partners, and fully develop. Finding the right environment to present a project, receive feedback, and connect with investors is key to transforming an innovation into a tangible reality. In this sense, BIOSPAIN offers a unique setting where biotechnology and health meet investment and strategic collaboration.

The BIOSPAIN Pitch Presentations provide a unique opportunity to showcase innovative projects in biotechnology and health to a global audience of investors, strategic partners, and leaders from the pharmaceutical and biotech industries. During these sessions, participants have six minutes to present their technological offering or business plan, creating valuable connections that can accelerate their company’s growth. They are only available to registered delegates, and a selection committee carefully reviews all applications to ensure that each presentation achieves maximum impact.

To gain first-hand insight into the value of this experience, we spoke with Germán Alejandro Sánchez Martín, Founder & CEO of Opportunity Health, the company that won the BIOSPAIN 2025 Pitch Presentations. In this interview, he shares how their participation in the Pitch Presentations allowed them to connect with new investors and strategic partners, as well as the advice they have for those considering participating in 2026.

AseBio: What motivated you to take part in the BIOSPAIN Pitch Presentations, and how did you prepare for your presentation?

Alejandro Sánchez Martín. Taking part in BIOSPAIN was a very clear opportunity for us: to be present at one of the main meeting points for the biotechnology sector in Europe and to present Opportunity Health to investors, corporates, and key players in the ecosystem.

We knew it wasn’t just another pitch, but a stage where the level is very high and where real opportunities are created. That’s why we took it very seriously.

Our preparation was highly focused: simplifying the message as much as possible, clearly explaining the problem — choking, which occurs suddenly and silently — and making it very clear what Yarnasa brings as a solution. We worked extensively to ensure the pitch was direct, easy to understand, and impactful, removing any unnecessary complexity.

In this process, the support of the innovation ecosystem in Navarra was key, especially the backing of CEIN, Sodena, and the Government of Navarra, which helped us better structure the project and prepare it for this type of setting.

Additionally, having our CTO, Nicolás López de Aguileta, deliver the pitch was crucial in conveying technical strength and credibility.

AseBio. What was the greatest benefit you gained from your participation in the last edition?

Alejandro Sánchez Martín. Without a doubt, visibility and external validation.

Winning the Start-up Pitch Contest among 43 high-level presentations was a turning point for us. Not only because of the recognition itself, but also because it immediately placed us on the radar of investors, strategic partners, and other key players in the sector.

From that point on, we started having more conversations, greater interest, and more real opportunities for collaboration. The award goes beyond symbolism—it has a direct impact on the project’s development.

AseBio. How did your presentation influence Opportunity Health’s visibility among investors or strategic partners?

Alejandro Sánchez Martín. The presentation at BIOSPAIN was a clear accelerator.

It allowed us to explain very directly what we are building: an automatic, self-applicable anti-choking device, designed to act within seconds in an emergency, without the need for third-party intervention.

That message, in an environment like BIOSPAIN—where specialized investors and major companies in the sector are present—creates an immediate impact.

In addition, being backed by a strong ecosystem like Navarra’s, with the support of entities such as CEIN and Sodena, reinforces stakeholders’ confidence and adds credibility to the project.

Since then, we have seen a clear increase in interest from investors and organizations interested in collaborating, especially in B2B environments such as nursing homes, social and healthcare centers, or public spaces where this type of solution can make a real difference.

AseBio. What advice would you give to other startups or companies considering presenting their project at BIOSPAIN 2026?

Alejandro Sánchez Martín. Prepare thoroughly and go all in.

BIOSPAIN is not just any event. The level is high and the time is very limited, so having a clear, direct, and easy-to-understand message is essential. It’s not about saying everything, but about saying what matters.

Our advice would be to focus on three things:
• Clearly explain the problem
• Make the value proposition explicit
• Convey why now is the right time

And above all, make the most of the event beyond the pitch. BIOSPAIN is about networking, meetings, conversations… that’s where a lot of things really happen.

If used well, it can be a turning point for the project.

BIOSPAIN 2026 will take place from September 29 to October 1 in Bilbao, once again becoming a global meeting point for innovation in biotechnology. We encourage all startups and emerging companies to present their projects at the Pitch Presentations and take advantage of this unique platform to connect with investors, strategic partners, and industry leaders, boosting their growth and international visibility.